1. HPV vaccination of immunocompromised hosts
- Author
-
Garland, SM, Brotherton, JML, Moscicki, AB, Kaufmann, AM, Stanley, M, Bhatla, N, Sankaranarayanan, R, de Sanjosé, S, Palefsky, JM, and behalf of IPVS, on
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Sexually Transmitted Infections ,Vaccine Related ,Cancer ,Cervical Cancer ,Prevention ,Immunization ,HPV and/or Cervical Cancer Vaccines ,Infectious Diseases ,3.4 Vaccines ,Prevention of disease and conditions ,and promotion of well-being ,Infection ,Good Health and Well Being ,Adolescent ,Child ,Female ,Guidelines as Topic ,Human Papillomavirus Recombinant Vaccine Quadrivalent ,Types 6 ,11 ,16 ,18 ,Humans ,Immunocompromised Host ,Immunogenicity ,Vaccine ,Papillomavirus Infections ,Papillomavirus Vaccines ,Vaccination ,Human papillomavirus ,Immunocompromised hosts ,HPV related cancers ,HPV Guidelines ,IPVS ,Medical microbiology ,Oncology and carcinogenesis - Abstract
It is well-established that immunocompromised people are at increased risk of HPV-related disease compared with those who are immunocompetent. Prophylactic HPV sub-unit vaccines are safe and immunogenic in immunocompromised people and it is strongly recommended that vaccination occur according to national guidelines. When delivered to immunocompromised populations, HPV vaccines should be given as a 3-dose regimen.
- Published
- 2017